logo-loader
HealthPharma & Biotech
Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals posts fiscal 1Q results showing healthy year-over-year rise in revenue

The drugmaker saw its revenue in the quarter to end June 2019 jump to C$16.1 million, up from C$3.2 million in the same quarter in the prior-year

Medexus Pharmaceuticals Inc - Medexus Pharmaceuticals posts fiscal 1Q results, reporting a healthy increase in revenue
Medexus also finished the quarter with cash and cash equivalents of C$27.4 million

Medexus Pharmaceuticals Inc (CVE:KMDP) (OTCMKTS:PDDPF) posted fiscal first-quarter results after the bell on Thursday showing a healthy year-over-year increase in revenue and positive underlying earnings.

The Montreal-based drugmaker saw its revenue in the quarter to end June 2019 jump to C$16.1 million, up from C$3.2 million in the same quarter in the prior-year. 

The company also finished the quarter with cash and cash equivalents of C$27.4 million, according to its statement.

READ: Medexus Pharmaceuticals 'extremely undervalued,' says Mackie

Other 1Q financial highlights for Medexus included:

  • Adjusted underlying earnings (EBITDA) of C$0.5 million, compared to a C$0.3 million loss in the year-ago quarter.
  • Gross profit of C$9.9 million, compared to C$1.7 million in the prior-year quarter.
  • Gross margin of 61.4%, compared to 53.5% in the prior-year quarter.
  • Net loss of C$2.2 million, compared to a C$0.7 million loss in the year-ago quarter.

Medexus CEO Ken d’Entremont said the surge in first quarter revenue stemmed from the acquisitions of October 2018 - when the firm merged the businesses of Pediapharm Inc, Medexus Inc and Medac Pharma Inc - as well as strong organic growth.  

“Importantly, we saw strong growth in each of the key product categories,” he said. “We were particularly pleased to have achieved positive adjusted EBITDA despite incurring incremental expenses related to the sales and marketing ramp-up for the allergy season, as well as our investment in a development project aimed at reformulating an existing FDA-approved product for use in the field of rheumatology.”

Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Medexus Pharmaceuticals Inc

Price: $3.99

Market: TSX-V
Market Cap: $58.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Medexus Pharmaceuticals unveils jump in 1Q revenue,...

Medexus Pharmaceuticals Inc (CVE:KMDP) (OTCMKTS:PDDPF) CEO Ken d'Entremont stopped by Proactive New York to talk about the Canadian-based biopharma's fiscal first-quarter results, which showed a year-over-year jump in revenue jump to C$16.1 million, and positive EBITDA of C$0.5...

2 weeks, 6 days ago

2 min read